Home About us Articles Multimedia Search Instructions Login 
5 years IF: 1.036 (® Thomson Reuters)
IF 2016: 1.064 (® Thomson Reuters)
Total Cites: 7140
Follow Us
Follow Us
  • Users Online: 1810
  • Home
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b

Ma Hui, Yang Rui-Feng, Li Xiao-He, Jin Qian, Wei Lai

Year : 2016| Volume: 129| Issue : 18 | Page no: 2212-2219

   This article has been cited by
 
1 Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection
M.-L. Wang,E.-Q. Chen,C.-M. Tao,H. Tang
Alimentary Pharmacology & Therapeutics. 2018; 47(12): 1719
[Pubmed]  [Google Scholar] [DOI]
2 Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy
Meng-Lan Wang,Juan Liao,Bing Wei,Dong-Mei Zhang,Ming He,Ming-Chuan Tao,En-Qiang Chen,Hong Tang
Infectious Diseases. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
3 Current advances in the elimination of hepatitis B in China by 2030
Shuye Zhang,Fusheng Wang,Zheng Zhang
Frontiers of Medicine. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection
L.-Y. Mak,D. K.-H. Wong,K.-S. Cheung,W.-K. Seto,C.-L. Lai,M.-F. Yuen
Alimentary Pharmacology & Therapeutics. 2017;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article
京ICP备05052599号